Research Analysts Issue Forecasts for Insmed FY2025 Earnings

Insmed Incorporated (NASDAQ:INSM) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Insmed in a research report issued to clients and investors on Wednesday, June 11th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings of ($5.05) per share for the year, up from their previous forecast of ($5.06). HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s FY2026 earnings at ($2.52) EPS, FY2027 earnings at $0.38 EPS and FY2029 earnings at $5.21 EPS.

Other equities analysts have also issued reports about the company. UBS Group cut their target price on Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Mizuho upped their price target on Insmed from $96.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday. Leerink Partners upped their price target on Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday. Royal Bank of Canada upped their price target on Insmed from $99.00 to $106.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Citigroup raised Insmed to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $104.81.

Insmed Stock Up 1.9%

NASDAQ INSM opened at $98.73 on Friday. The business has a 50 day moving average price of $70.73 and a two-hundred day moving average price of $73.47. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $100.00. The stock has a market cap of $17.98 billion, a PE ratio of -17.66 and a beta of 0.80. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.06) EPS.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Insmed by 3.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after purchasing an additional 186 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Insmed by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company’s stock worth $29,590,000 after purchasing an additional 32,960 shares in the last quarter. Values First Advisors Inc. increased its holdings in shares of Insmed by 4.4% during the 4th quarter. Values First Advisors Inc. now owns 5,199 shares of the biopharmaceutical company’s stock valued at $359,000 after acquiring an additional 221 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Insmed by 9.6% during the 4th quarter. Rhumbline Advisers now owns 288,337 shares of the biopharmaceutical company’s stock valued at $19,907,000 after acquiring an additional 25,292 shares during the last quarter.

Insider Activity

In related news, insider Michael Alexander Smith sold 4,407 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $67.81, for a total value of $298,838.67. Following the completion of the sale, the insider now directly owns 92,203 shares of the company’s stock, valued at approximately $6,252,285.43. This represents a 4.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $25,742,347.58. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 319,932 shares of company stock valued at $25,733,693 over the last three months. Insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.